The animal health group Intervacc AB (publ) has appointed Anna-Carin Lagerlöf to the newly established role as Sales and Marketing Director. In this position, Anna-Carin will lead the company's continued sales growth, with a particular focus on Strangvac - Intervacc's vaccine against strangles, a common infectious disease in horses. Anna-Carin brings extensive experience from the animal health market and joins Intervacc from IDEXX Laboratories, where she served as Country Manager for the Nordics. She will assume her new role in November and will also become a member of the company's executive management team.

"Anna-Carin Lagerlöf possesses solid expertise in the sales of products and services within animal health. In recent years, she has led the Nordic operations for IDEXX, a US-based multinational company and market leader in veterinary diagnostics. She has a passionate interest in animal welfare, and I look forward to working with Anna-Carin as we continue our growth journey" says Jonas Sohlman, CEO of Intervacc.

Intervacc develops vaccines for animals and earlier this year reported strong sales growth in Europe, along with progress in the regulatory approval process for Strangvac in the United States. The company's distribution partner, Dechra, has introduced the vaccine in several additional European markets during the year. At the beginning of the summer, Dechra launched Strangvac in Finland, and more recently the vaccine was introduced in Spain, Portugal, and Slovenia.

"I am incredibly proud to be joining Intervacc and to help realise the full market potential of Strangvac. It is now time to translate the remarkable development journey into tangible results. With experience from having quintupled IDEXX's Nordic sales, I know how to execute plans swiftly and with determination. Together, we will build strong demand and establish Strangvac as the natural choice for veterinarians and horse owners worldwide," comments Anna-Carin Lagerlöf.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on September 25, 2025, 08.30 CET.

About Strangvac

Strangvac is a vaccine against equine strangles and is approved for sale and marketing in the EU as well as in the United Kingdom, Iceland, Norway, and Liechtenstein. It has been launched in Sweden, Denmark, Finland, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.

About Intervacc

Intervacc AB is a group operating within animal health, specialising in the development of vaccines for animals. The company develops and markets vaccines against animal diseases based on its proprietary technology platform using fused recombinant proteins. The Intervacc share is listed on the Nasdaq First North Growth Market.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10